These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 36609487)

  • 1. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
    Ding L; Wang Q; Martincuks A; Kearns MJ; Jiang T; Lin Z; Cheng X; Qian C; Xie S; Kim HJ; Launonen IM; Färkkilä A; Roberts TM; Freeman GJ; Liu JF; Konstantinopoulos PA; Matulonis U; Yu H; Zhao JJ
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36609487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer.
    Wang Q; Bergholz JS; Ding L; Lin Z; Kabraji SK; Hughes ME; He X; Xie S; Jiang T; Wang W; Zoeller JJ; Kim HJ; Roberts TM; Konstantinopoulos PA; Matulonis UA; Dillon DA; Winer EP; Lin NU; Zhao JJ
    Nat Commun; 2022 May; 13(1):3022. PubMed ID: 35641483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 4. Adenosine receptor A2b confers ovarian cancer survival and PARP inhibitor resistance through IL-6-STAT3 signalling.
    Chi L; Huan L; Zhang C; Wang H; Lu J
    J Cell Mol Med; 2023 Aug; 27(15):2150-2164. PubMed ID: 37278400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer.
    Bustos MA; Yokoe T; Shoji Y; Kobayashi Y; Mizuno S; Murakami T; Zhang X; Sekhar SC; Kim S; Ryu S; Knarr M; Vasilev SA; DiFeo A; Drapkin R; Hoon DSB
    Cell Biosci; 2023 Nov; 13(1):200. PubMed ID: 37932806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP Inhibition Activates STAT3 in Both Tumor and Immune Cells Underlying Therapy Resistance and Immunosuppression In Ovarian Cancer.
    Martincuks A; Song J; Kohut A; Zhang C; Li YJ; Zhao Q; Mak E; Rodriguez-Rodriguez L; Yu H; Cristea M
    Front Oncol; 2021; 11():724104. PubMed ID: 34956861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer.
    Martincuks A; Zhang C; Austria T; Li YJ; Huang R; Lugo Santiago N; Kohut A; Zhao Q; Borrero RM; Shen B; Cristea M; Wang EW; Song M; Rodriguez-Rodriguez L; Yu H
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
    Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
    Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring Molecular Drivers of PARPi Resistance in BRCA1-Deficient Ovarian Cancer: The Role of LY6E and Immunomodulation.
    Petta TB; Carlson J
    Int J Mol Sci; 2024 Sep; 25(19):. PubMed ID: 39408764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer.
    Liu C; Li J; Xu F; Chen L; Ni M; Wu J; Zhao H; Wu Y; Li J; Wu X; Chen X
    Mol Cancer; 2024 May; 23(1):111. PubMed ID: 38778348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
    Yazinski SA; Comaills V; Buisson R; Genois MM; Nguyen HD; Ho CK; Todorova Kwan T; Morris R; Lauffer S; Nussenzweig A; Ramaswamy S; Benes CH; Haber DA; Maheswaran S; Birrer MJ; Zou L
    Genes Dev; 2017 Feb; 31(3):318-332. PubMed ID: 28242626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
    Kim H; Xu H; George E; Hallberg D; Kumar S; Jagannathan V; Medvedev S; Kinose Y; Devins K; Verma P; Ly K; Wang Y; Greenberg RA; Schwartz L; Johnson N; Scharpf RB; Mills GB; Zhang R; Velculescu VE; Brown EJ; Simpkins F
    Nat Commun; 2020 Jul; 11(1):3726. PubMed ID: 32709856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
    Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
    [No Abstract]   [Full Text] [Related]  

  • 14. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
    Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
    Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation.
    Hu X; Zhao M; Bai M; Xue Z; Wang F; Zhu Z; Yu J; Yue J
    Cancer Lett; 2024 Apr; 586():216676. PubMed ID: 38278469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
    Shen J; Zhao W; Ju Z; Wang L; Peng Y; Labrie M; Yap TA; Mills GB; Peng G
    Cancer Res; 2019 Jan; 79(2):311-319. PubMed ID: 30482774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
    Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
    Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in
    Kim H; George E; Ragland R; Rafail S; Zhang R; Krepler C; Morgan M; Herlyn M; Brown E; Simpkins F
    Clin Cancer Res; 2017 Jun; 23(12):3097-3108. PubMed ID: 27993965
    [No Abstract]   [Full Text] [Related]  

  • 20. N
    Fukumoto T; Zhu H; Nacarelli T; Karakashev S; Fatkhutdinov N; Wu S; Liu P; Kossenkov AV; Showe LC; Jean S; Zhang L; Zhang R
    Cancer Res; 2019 Jun; 79(11):2812-2820. PubMed ID: 30967398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.